Clinical Development Lead, Transplant Expansion / New Indications - Remote

Overview

The Biogen West Coast Hub (WCH) is focused on transforming the lives of patients with severe immune-mediated diseases by developing novel targeted therapies with outsized clinical impact, faster. To accomplish this for transplant recipients, we are seeking a highly motivated and experienced Clinical Development Lead for our expansion beyond our ongoing Phase 3 trial in late antibody-mediated rejection.

In Short

• Represent the Biogen West Coast Hub Development team and influence decision-making in relevant governance and strategic forums.
• Identify additional transplant indications for felzartamab, differentiating it from current market competitors.
• Build and strengthen relationships with internal and external stakeholders.
• Employ innovative approaches for rare disease drug development.
• Design and implement a robust felzartamab framework.
• Coordinate with study team members to develop well-structured protocols.
• Support regulatory filings and clinical translational studies.
• Serve as subject matter expert on safety reviews.
• Present at investigator meetings and contribute to data analysis.
• Integrate scientific rationale with regulatory and commercial goals.

Requirements

• MD degree with board certification in nephrology, immunology, or a similar field.
• 5-7 years of clinical drug development experience in pharma/biotech.
• Broad knowledge of clinical science, particularly in transplant and immunological areas.
• Demonstrated leadership abilities in a team-oriented environment.
• Exceptional interpersonal skills.
• Proven problem-solving and analytical capabilities.
• Experience facilitating discussions among cross-functional groups.
• Willingness to travel domestically and internationally.

Benefits

• Medical, Dental, Vision, & Life insurances.
• Fitness & Wellness programs.
• Short- and Long-Term Disability insurance.
• Paid vacation and holidays.
• 401(k) program with company matched contributions.
• Tuition reimbursement up to $10,000 per year.